Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Esanex Inc. Identifier:
First received: March 27, 2008
Last updated: May 15, 2012
Last verified: May 2012
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Condition Intervention Phase
Solid Tumor Malignancy
Lymphoid Malignancy (Lymphoma and CLL)
Drug: SNX-5422 Mesylate Hsp90 inhibitor
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas

Resource links provided by NLM:

Further study details as provided by Esanex Inc.:

Primary Outcome Measures:
  • MTD, safety and toxicity [ Time Frame: continuous ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • pharmacokinetic profile of SNX-5422 [ Time Frame: first cycle ] [ Designated as safety issue: No ]
  • tumor response measured by X-rays or scans [ Time Frame: after every 2 cycles ] [ Designated as safety issue: No ]

Enrollment: 32
Study Start Date: March 2008
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm Drug: SNX-5422 Mesylate Hsp90 inhibitor
dose escalated, tablets twice a week; undetermined duration until disease progression


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Solid tumors or lymphoid malignancies refractory to standard therapy
  • measurable disease
  • recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
  • no chemotherapy within 4 weeks of entering study
  • Age > 18 years
  • Karnofsy >= 60%
  • Life expectancy > 3 months
  • normal or adequate organ and marrow function

Exclusion Criteria:

  • receiving other investigational agents
  • brain metastases
  • uncontrolled medical illness
  • HIV+ receiving combination antiretroviral therapy
  • significant GI disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00647764

United States, Maryland
Pfizer Investigational Site
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Esanex Inc.
National Cancer Institute (NCI)
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00647764     History of Changes
Other Study ID Numbers: B1311003  PO7318 
Study First Received: March 27, 2008
Last Updated: May 15, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type processed this record on May 25, 2016